Verve Therapeutics (VERV): Growth-Adjusted Payback Ratio

Brandmark of vervetx.com (VERV)

The weighted PEG ratio indicates that the metric is fixed at 0.00. Verve Therapeutics (VERV) dominates cardiac gene editing thanks to unique patents that preclude dumping. High barriers to entry and lobbyist support are coupled with strict FDA oversight. However, the experimental nature of the therapy and the risk of side effects create uncertainty regarding commercialization timelines.

Verve Therapeutics - VERV PEG Multiple (period 07/04/2022 - 08/09/2025)

Verve Therapeutics (VERV) - metric breakdowns and financial figures

- current quotes and average value forecast:
Market Price vervetx.com|VERV - Price Target Chart
- stock exchange capitalization data:
Market Value Verve|VERV - Real Price to Acquire Entire Company
- book capitalization indicators:
Net Assets per Single Share Verve Therapeutics|VERV - Book Capitalization|Market-to-Book Ratio vervetx.com|VERV - Cumulative Company Assets
- business debt structure and liquidity details:
All Debt to Shareholders' Equity Ratio Verve Therapeutics|VERV - Long-Term Debt to Equity Ratio|Short-Term Loans to Capital Ratio vervetx.com|VERV - Company Aggregate Debts|Debt to Net Assets Ratio Verve|VERV - Company Long-Term Debts|Short-Term Debt Verve Therapeutics|Intermediate Coverage Ratio vervetx.com
- financial results and valuation multiples details:
VERV - Net Profit|Projected Future Earnings Verve Therapeutics|VERV - Price to Earnings Ratio|Price to Expected Earnings Ratio vervetx.com|VERV - PEG Multiple|Company Value to EBITDA Verve|VERV - Operating profit before deduction of amortization|Net earnings per share (EPS TTM) Verve Therapeutics|VERV - Net earnings per share for the last 12 months|Year-over-year earnings per share growth rate for the last twelve months vervetx.com|VERV - Earnings growth in current year|Consensus forecast of earnings per share growth for next year Verve Therapeutics
General company analysis:Verve Therapeutics Inc., VERV
Finished products of Verve

Investors utilize multiples to verify the fundamental stability of an issuer, separating speculative noise from real growth potential. By analyzing the valuation-to-earnings growth ratio, you correlate the market value of Verve Therapeutics (VERV) with its earnings growth rate, which, combined with the creation of strategic buffers of gene-editing components, confirms the company's operational readiness for scaling at a value below one.

Competing companies

REGN - Price to Earnings Adjusted for Growth Rate|Price/Earnings to Growth Ratio iRhythm Technologies Inc IRTC|Growth-Adjusted Payback Ratio LNTH|MLYS: Price/Earnings to Growth Multiple|HTFL: Price/Earnings to Growth Ratio|KMTS: PEG Multiple|Price to Earnings Adjusted for Growth Rate Esperion Therapeutics, Inc. (ESPR)|Price/Earnings to Growth Multiple AMRN|AVR: Growth-Adjusted Payback Ratio|Price/Earnings to Growth Multiple TNYA (Tenaya Therapeutics)|Company Value to Earnings Growth Ratio CVRX|PEG Multiple MIST (Milestone Pharmaceuticals Inc.)|Growth-Adjusted Payback Ratio CRDL|HeartBeam Corp - PEG Multiple|Price to Earnings Adjusted for Growth Rate Tenax Therapeutics Inc|Adagio Medical Holdings (ADGM) - Price/Earnings to Growth Ratio|biocardia.com - Growth-Adjusted Payback Ratio|VTAK (Catheter Precision, Inc.) - PEG Multiple|PEG Multiple ARCA Bio|Price/Earnings to Growth Ratio Acasti Pharma (ACST)|AVTE: Market Cap to Earnings and Growth Ratio|PEG Multiple WINT (Windtree Therapeutics, Inc.)